Diabetic nephropathy. Diabetes mellitus due to underlying condition with diabetic nephropathy
Conditions
Interventions
Intervention 1: The intervention group will receive crocin supplement (produced by Sami Saz Company) for 12 weeks. Each tablets contains 30 mg of crocin. The tablets will be provided to the patients i
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with diabetic nephropathy aged 40 to 75 years Moderate blood pressure (systolic pressure 140-160 and diastolic pressure 90-100 mm Hg) Absence of urinary tract infection and any other disease that can cause proteinuria Glomerular filtration rate more than 60 milliliters per minute.
Exclusion criteria
Exclusion criteria: Taking antioxidant supplements from three months before entering the study. Patients who do not want to participate in the study or do not take medication regularly. Taking steroidal immunosuppressive drugs (corticosteroids). Suffering from certain cardiovascular diseases, cancer, inflammatory diseases, autoimmune disorders, or hyper- or hypothyroidism. Taking anticoagulants. Having high blood pressure (systolic pressure above 140 and diastolic pressure above 90 mm Hg). pregnancy Smoking and alcohol use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Creatinine. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: Enzymatic assay kit.;Blood Urea Nitrogen. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: Enzymatic assay kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood sugar. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: Enzymatic assay kit.;Serum concentrations of insulin. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: ELISA kit.;Homeostatic model assessment for Insulin Resistance Index (HOMA-IR). Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: The HOMA-IR Index is calculated using fasting glucose and fasting insulin levels.;Serum concentrations of triglyceride. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: Enzymatic assay kit.;HDL-C cholesterol. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: Enzymatic assay kit.;Total cholesterol. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: Enzymatic assay kit.;LDL cholesterol. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: Enzymatic assay kit.;Evaluation of the serum level of Cystatin-C parameter. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: ELISA kit.;Nitric oxide. Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: ELISA kit.;Serum concentrations of high sensitivity c-reactive protein (hs-CRP). Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: ELISA kit.;Serum concentrations of Interleukin 6 (IL-6). Timepoint: Initially (before the intervention) and at the end (12 weeks after the intervention). Method of measurement: ELISA kit.;Serum concentration of Total antioxid | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZeinab Mokhtari
Esfahan University of Medical Sciences
Outcome results
None listed